Brief: Dyne Therapeutics Announces Positive Topline Results From Phase 1/2 Deliver Trial
08/12/2025 12:11
Dec 8 (Reuters) - Dyne Therapeutics Inc DYN.O: DYNE THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 1/2 DELIVER TRIAL OF Z-ROSTUDIRSEN IN DUCHENNE MUSCULAR DYSTROPHY (DMD) DYNE THERAPEUTICS INC - REC SHOWS SIGNIFICANT INCREASE IN DYSTROPHIN EXPRESSION TO 5.46% DYNE THERAPEUTICS INC: REGISTRATIONAL EXPANSION COHORT (REC) MET PRIMARY ENDPOINT DYNE THERAPEUTICS INC - SUBMISSION FOR U.S. ACCELERATED APPROVAL ON TRACK FOR Q2 2026 DYNE THERAPEUTICS INC - Z-ROSTUDIRSEN SHOWS FAVORABLE SAFETY PROFILE Source text: ID:nGNX4dZKnL Further company coverage: DYN.O ((Reuters.Briefs@thomsonreuters.com;))